Episode 9- Ozempic, Mounjaro, Wegovy....A Dietitian's Opinion

In this podcast episode, Kylie and Spencer explore the emerging trend of weight loss injections like Ozempic, Wegovy, and Mounjaro, diving into their science and societal impact. They trace the history of and evolution leading to GLP-1 receptor agonists. These injectable medications, initially approved for Type 2 Diabetes, are now gaining traction for weight management and cardiovascular benefits, offering up to 15-20% weight loss and reduced A1C levels. The hosts unpack the mechanism of action—how GLP-1 mimics natural hormones to stimulate insulin, suppress glucagon, slow digestion, and enhance leptin signaling for fullness. They discuss accessibility challenges, from high costs to compounded alternatives, along with the FDA's stance on safety concerns. The episode also highlights risks like nausea, thyroid cancer, and weight regain post-treatment, while emphasizing the importance of pairing these medications with lifestyle changes for sustainable health. With insights into their impacts on heart and kidney diseases, the hosts encourage informed decision-making, advocating for body autonomy amidst growing societal judgment.